Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 115
- Registration Number
- NCT00425035
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 39
- Registration Number
- NCT00418665
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 266
- Registration Number
- NCT00418938
Etanercept SFP in RA Patients
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 224
- Registration Number
- NCT00413452
Study of Transitioning From Alendronate to Denosumab
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 504
- Registration Number
- NCT00377819
STAAR-2 Clinical Study
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 618
- Registration Number
- NCT00368901
STAAR-1 Clinical Study
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2000
- Registration Number
- NCT00369772
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 468
- Registration Number
- NCT00356590
16.0040 Ankylosing Spondylitis Study
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 257
- Registration Number
- NCT00356356
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1186
- Registration Number
- NCT00339183
© Copyright 2024. All Rights Reserved by MedPath